But even in the absence of a dedicated grouping, the prospect of intellectual property approval has sparked a vigorous debate over whether long-used names for the drug can be trademarked.
I welcome this opportunity to jointly explore how drug procurement practices, intellectual property policies, competition policies, and ultimately prices can improve access to medicines.